Bleeding Disorders
News
EC approves emicizumab for hemophilia A with inhibitors
The European Commission (EC) has granted marketing authorization for emicizumab (Hemlibra®), a bispecific factor IXa- and factor X-directed...
News
Gene therapy for hemophilia A gets fast-track review
The FDA has granted breakthrough therapy designation to a gene therapy product aimed at hemophilia A.
News
Team creates device to study hemostasis
Researchers have engineered a miniature model system for studying hemostasis. They believe the device could serve as a drug discovery platform...
News
Product seems effective for ITI in severe hemophilia A
Results of a retrospective study suggest a recombinant factor VIII Fc fusion protein (rFVIIIFc) can be effective for immune tolerance induction (...
News
Product increases FIX levels in hemophilia B
MADRID—The recombinant factor IX (FIX) product CB 2679d/ISU304 can increase FIX levels in patients with severe hemophilia B, according to a phase...
News
Factor IX product launched in US
The recombinant, GlycoPEGylated coagulation factor IX product Rebinyn® is now available in the US for the treatment of patients with hemophilia B...
Feature
Hemophilia A drug heads toward approval in Europe
The drug was approved by the U.S. Food and Drug Administration in November 2017.
News
IV bevacizumab improves severe bleeding in HHT
Intravenous (IV) bevacizumab “dramatically” improves severe bleeding associated with hereditary hemorrhagic telangiectasia (HHT), according to...
News
CHMP recommends approval of emicizumab
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of emicizumab (Hemlibra®), a...
Feature
Gene therapy moves from promise to reality
Dr. Cynthia Dunbar, of the NIH, talks about the “critical mass of successes” in hematology and what is coming in the future.
From the Journals
Sotatercept promising for treatment of anemia in MDS
The phase 2 trial included patients who did not respond to erythropoiesis-stimulating agents.